UY35918A - Formas cristalinas de un compuesto antiviral - Google Patents

Formas cristalinas de un compuesto antiviral

Info

Publication number
UY35918A
UY35918A UY0001035918A UY35918A UY35918A UY 35918 A UY35918 A UY 35918A UY 0001035918 A UY0001035918 A UY 0001035918A UY 35918 A UY35918 A UY 35918A UY 35918 A UY35918 A UY 35918A
Authority
UY
Uruguay
Prior art keywords
crystal forms
antiviral compound
compound
forms
dioxadiazacycloneonedecino
Prior art date
Application number
UY0001035918A
Other languages
English (en)
Inventor
Chan Johann
Bringley Dustin
Fung Peter
Keaton Katie
Lapina Olga
Morrison Henry
Pcion Dominika
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of UY35918A publication Critical patent/UY35918A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

Se prepararon formas cristalinas del compuesto anti-HCV (1aR,5S,8S,9S,10R,22aR)-5-terc-butil-N-[(1R,2R)-2-(difluorometil)-1-{[(1-metilciclopropil)sulfonil]carbamoil}ciclopropil]-9-etil-18,18-difluoro-14-metoxi-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahidro-8H-7,10-metanociclopropa[18,19][1,10,3,6]dioxadiazaciclononadecino[11,12-b]quinoxalina-8-carboxamida (Compuesto I) y se caracterizaron en estado sólido:También se proporcionan procesos de fabricación y métodos para usar las formas cristalinas.
UY0001035918A 2013-12-23 2014-12-23 Formas cristalinas de un compuesto antiviral UY35918A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361920427P 2013-12-23 2013-12-23

Publications (1)

Publication Number Publication Date
UY35918A true UY35918A (es) 2015-05-29

Family

ID=52282995

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035918A UY35918A (es) 2013-12-23 2014-12-23 Formas cristalinas de un compuesto antiviral

Country Status (12)

Country Link
US (2) US9562058B2 (es)
EP (1) EP3087086B1 (es)
JP (2) JP6568541B2 (es)
AR (1) AR098958A1 (es)
AU (1) AU2014370124A1 (es)
CA (1) CA2934049A1 (es)
ES (1) ES2708993T3 (es)
NZ (1) NZ720887A (es)
PT (1) PT3087086T (es)
TW (1) TW201609752A (es)
UY (1) UY35918A (es)
WO (1) WO2015100144A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320610B (zh) 2013-12-23 2023-06-06 吉利德科学公司 大环hcv ns3抑制三肽的合成
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
CN111372592A (zh) 2017-12-07 2020-07-03 埃默里大学 N4-羟基胞苷及衍生物和与其相关的抗病毒用途
CN115417803B (zh) * 2022-08-30 2023-10-03 四川同晟生物医药有限公司 乌帕替尼中间体(3r,4s)-1-苄氧羰基-4-乙基吡咯烷-3-羧酸的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
ES2491090T3 (es) * 2008-07-22 2014-09-05 Merck Sharp & Dohme Corp. Combinaciones de un compuesto de quinoxalina macrocíclica que es un inhibidor de la proteasa NS3 del VHC con otros agentes del VHC
NZ608720A (en) * 2010-09-21 2015-03-27 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
EP2618665A4 (en) * 2010-09-21 2014-08-20 Merck Sharp & Dohme HCV NS3 PROTEASE INHIBITORS
PL3431477T3 (pl) 2011-11-16 2021-04-06 Gilead Pharmasset Llc Skondensowane imidazoliloimidazole jako związki przeciwwirusowe
UA119315C2 (uk) * 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с

Also Published As

Publication number Publication date
US9862728B2 (en) 2018-01-09
AU2014370124A1 (en) 2016-06-23
JP6568541B2 (ja) 2019-08-28
AR098958A1 (es) 2016-06-22
ES2708993T3 (es) 2019-04-12
CA2934049A1 (en) 2015-07-02
US9562058B2 (en) 2017-02-07
JP2017503016A (ja) 2017-01-26
WO2015100144A1 (en) 2015-07-02
EP3087086B1 (en) 2018-11-07
US20170267694A1 (en) 2017-09-21
EP3087086A1 (en) 2016-11-02
NZ720887A (en) 2018-01-26
US20150175625A1 (en) 2015-06-25
TW201609752A (zh) 2016-03-16
JP2019089819A (ja) 2019-06-13
PT3087086T (pt) 2019-02-06

Similar Documents

Publication Publication Date Title
GT201700136A (es) Formas sólidas de un inhibidor ask 1
DK3699181T3 (da) Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
UY35918A (es) Formas cristalinas de un compuesto antiviral
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
EP3254654A4 (en) Stretch structure for absorbent article, and underpants-type disposable diaper using same
EA201691991A1 (ru) Мультиспецифические антитела
TWD170353S (zh) 項鍊
TWD169700S (zh) 針盤
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
EP2947455A4 (en) HYDROCHROMIC POLYDIACETYLENE COMPOSITE COMPOSITION, HYDROCHROMIC THIN FILM USING THE SAME AND USE THEREOF
EP3578590A4 (en) POLYIMIDE PRECURSOR SOLUTION AND POLYIMIDE FILM PRODUCED THEREFROM
EP3326413A4 (en) USER PLAN FOR FIFTH GENERATION CELLULAR ARCHITECTURE
DOP2017000288A (es) Moduladores alostéricos positivos del receptor muscarínico m2.
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
EP3467911A4 (en) NEGATIVE ELECTRODE ACTIVE MATERIAL, MIXED NEGATIVE ELECTRODE ACTIVE MATERIAL, AND METHOD FOR PRODUCING NEGATIVE ELECTRODE ACTIVE MATERIAL
EP3467912A4 (en) NEGATIVE ELECTRODE ACTIVE MATERIAL, MIXED NEGATIVE ELECTRODE ACTIVE MATERIAL, AND METHOD FOR PRODUCING NEGATIVE ELECTRODE ACTIVE MATERIAL
EP3476806A4 (en) SOLUTION, METHOD FOR PRODUCING THE SAME AND METHOD FOR PRODUCING AN ACTIVE SUBSTANCE OF A SECONDARY BATTERY
EP3279254A4 (en) Polypropylene for film condenser, biaxial stretching film for film condenser, film condenser and manufacturing methods therefor
AU2015352158A8 (en) Medicaments for slowing Parkinson's Disease
EP3467913A4 (en) NEGATIVE ELECTRODE ACTIVE MATERIAL, MIXED NEGATIVE ELECTRODE ACTIVE MATERIAL AND METHOD FOR PRODUCING A NEGATIVE ELECTRODE ACTIVE MATERIAL
EP3242348A4 (en) Method for producing positive active material precursor and positive active material for lithium secondary batteries, exhibiting concentration gradient, and positive active material precursor and positive active material for lithium secondary batteries, exhibiting concentration gradient, produced by same
EP3067969A4 (en) Negative electrode material for secondary battery, and secondary battery using same
WO2014146111A3 (en) Analgesic compounds and methods of use
EP3236520A4 (en) Negative-electrode active material for electrical device, and electrical device using same
EP3376570A4 (en) Negative-electrode active material for electrical device, and electrical device in which said material is used

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211230